Literature DB >> 21537333

Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia.

S Schnittger1, U Bacher, W Kern, T Alpermann, C Haferlach, T Haferlach.   

Abstract

High FLT3-ITD/wildtype (wt) load in FLT3-ITD-mutated AML has been associated with adverse impact on outcome in several studies. To clarify whether FLT3-ITD load as expressed as FLT3-ITD/wt ratio is also relevant in patients with NPM1 mutated AML, we assessed the FLT3-ITD mutation status and FLT3-ITD/wt ratio by fragment analysis in 638 NPM1mut AML (339 females; 299 males; 17.8-88.0 years), and analyzed its prognostic relevance in 355 patients. FLT3-ITD of various length and load were detected in 243/638 cases (38.1%). Median EFS (19.3 vs 9.7 months, P<0.001) and median 2-year survival rate (72.0 vs 52.7%, P=0.006) was better in FLT3wt (n=212 with available follow-up data) than FLT3-ITD (n=143). A higher FLT3-ITD/wt ratio as continuous variable was correlated with a shorter EFS (P=0.028). When patients were separated into subgroups according to the FLT3-ITD mutation load, only a FLT3-ITD/wt ratio 0.5 conferred an independent adverse impact on EFS and OS, and retained its prognostic significance also in multivariate analysis (P=0.009 for EFS, P=0.008 for OS). In conclusion, for risk estimation in NPM1 mutated AML not only the FLT3-ITD status, but also the FLT3-ITD load has to be taken into account. These data might contribute to clinical decision making in AML.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21537333     DOI: 10.1038/leu.2011.97

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  38 in total

1.  Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous Leukemia.

Authors:  Betül Oran; Jorge Cortes; Amer Beitinjaneh; Hsiang-Chun Chen; Marcos de Lima; Keyur Patel; Farhad Ravandi; Xuemei Wang; Mark Brandt; Borje S Andersson; Stefan Ciurea; Fabio P Santos; Leandro de Padua Silva; Elizabeth J Shpall; Richard E Champlin; Hagop Kantarjian; Gautam Borthakur
Journal:  Biol Blood Marrow Transplant       Date:  2016-04-04       Impact factor: 5.742

2.  Clinical impact of FLT3 mutation load in acute promyelocytic leukemia with t(15;17)/PML-RARA.

Authors:  Susanne Schnittger; Ulrike Bacher; Claudia Haferlach; Wolfgang Kern; Tamara Alpermann; Torsten Haferlach
Journal:  Haematologica       Date:  2011-08-22       Impact factor: 9.941

3.  Impact of FLT3 ITD/NPM1 mutation status in adult patients with acute myelocytic leukemia autografted in first remission.

Authors:  Norbert-Claude Gorin; Myriam Labopin; Giovanna Meloni; Arnaud Pigneux; Jordi Esteve; Mohty Mohamad
Journal:  Haematologica       Date:  2012-08-28       Impact factor: 9.941

4.  The role of different genetic subtypes of CEBPA mutated AML.

Authors:  A Fasan; C Haferlach; T Alpermann; S Jeromin; V Grossmann; C Eder; S Weissmann; F Dicker; A Kohlmann; S Schindela; W Kern; T Haferlach; S Schnittger
Journal:  Leukemia       Date:  2013-09-23       Impact factor: 11.528

Review 5.  FLT3-ITD and its current role in acute myeloid leukaemia.

Authors:  Francisco Alejandro Lagunas-Rangel; Venice Chávez-Valencia
Journal:  Med Oncol       Date:  2017-05-03       Impact factor: 3.064

6.  High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML.

Authors:  Sanjay S Patel; Frank C Kuo; Christopher J Gibson; David P Steensma; Robert J Soiffer; Edwin P Alyea; Yi-Bin A Chen; Amir T Fathi; Timothy A Graubert; Andrew M Brunner; Martha Wadleigh; Richard M Stone; Daniel J DeAngelo; Valentina Nardi; Robert P Hasserjian; Olga K Weinberg
Journal:  Blood       Date:  2018-05-03       Impact factor: 22.113

7.  Genomic Profiling of Pediatric Acute Myeloid Leukemia Reveals a Changing Mutational Landscape from Disease Diagnosis to Relapse.

Authors:  Jason E Farrar; Heather L Schuback; Rhonda E Ries; Daniel Wai; Oliver A Hampton; Lisa R Trevino; Todd A Alonzo; Jaime M Guidry Auvil; Tanja M Davidsen; Patee Gesuwan; Leandro Hermida; Donna M Muzny; Ninad Dewal; Navin Rustagi; Lora R Lewis; Alan S Gamis; David A Wheeler; Malcolm A Smith; Daniela S Gerhard; Soheil Meshinchi
Journal:  Cancer Res       Date:  2016-03-03       Impact factor: 12.701

8.  Prognostic impact of low allelic ratio FLT3-ITD and NPM1 mutation in acute myeloid leukemia.

Authors:  Masahiro Sakaguchi; Hiroki Yamaguchi; Yuho Najima; Kensuke Usuki; Toshimitsu Ueki; Iekuni Oh; Sinichiro Mori; Eri Kawata; Nobuhiko Uoshima; Yutaka Kobayashi; Shinichi Kako; Kenji Tajika; Seiji Gomi; Katsuhiro Shono; Kensuke Kayamori; Masao Hagihara; Junya Kanda; Hitoji Uchiyama; Junya Kuroda; Naoyuki Uchida; Yasushi Kubota; Shinya Kimura; Saiko Kurosawa; Nana Nakajima; Atsushi Marumo; Ikuko Omori; Yusuke Fujiwara; Shunsuke Yui; Satoshi Wakita; Kunihito Arai; Tomoaki Kitano; Kazuhiko Kakihana; Yoshinobu Kanda; Kazuteru Ohashi; Takahiro Fukuda; Koiti Inokuchi
Journal:  Blood Adv       Date:  2018-10-23

9.  Subtype-specific patterns of molecular mutations in acute myeloid leukemia.

Authors:  D Rose; T Haferlach; S Schnittger; K Perglerová; W Kern; C Haferlach
Journal:  Leukemia       Date:  2016-06-10       Impact factor: 11.528

Review 10.  FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations.

Authors:  Sabine Kayser; Mark J Levis
Journal:  Leuk Lymphoma       Date:  2013-06-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.